The primary patent for Lucentis (ranibizumab), developed by Genentech, is set to expire in July 2024 [1]. This expiration date pertains to U.S. Patent No. 7,723,508 [1].
When does exclusivity for Lucentis end?
Lucentis's core patent expiration marks a significant event for market access [1]. While the exact date for patent expiry is July 25, 2024, other related patents and regulatory exclusivities might influence market entry timelines [1].
What happens when the Lucentis patent expires?
Following patent expiration, the market is expected to open up for biosimilar versions of Lucentis [2]. Biosimilars are highly similar to the reference biologic drug, offering comparable safety and efficacy, potentially at a lower cost [2].
Can biosimilars for Lucentis enter before patent expiry?
The entry of biosimilars is typically dependent on the expiration of all relevant patents and exclusivities. While the main patent expires in July 2024, other patents or legal challenges could affect the precise timing of biosimilar market entry [1].
Who makes biosimilar versions of Lucentis?
Several companies are developing biosimilar versions of ranibizumab. These include Samsung Bioepis, BioAtrophin, and Alvotech, among others [3]. These companies are in various stages of development and regulatory approval processes for their biosimilar candidates.
How do Lucentis biosimilars compare to the original drug?
Biosimilars are designed to be highly similar to the reference product, Lucentis, in terms of their molecular structure, biological activity, safety, and efficacy [2]. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), conduct rigorous reviews to ensure biosimilars meet these standards.
What is the likely impact of Lucentis patent expiry on pricing?
The introduction of biosimilars is generally anticipated to lead to reduced pricing for ranibizumab treatments [2]. This increased competition can make therapies more accessible to patients and healthcare systems.
Are there any ongoing patent challenges for Lucentis?
Patent litigation is common in the pharmaceutical industry. Companies developing biosimilars often challenge existing patents, and the outcomes of these legal battles can impact the market entry timeline for biosimilars [1]. Specific details of any ongoing challenges for Lucentis patents can be found through resources like DrugPatentWatch.com [1].
What are the regulatory steps for Lucentis biosimilars?
To be approved, biosimilars must undergo a comprehensive review process by regulatory bodies like the FDA. This process demonstrates that the biosimilar is highly similar to the reference product and has no clinically meaningful differences in terms of safety, purity, and potency [2].
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration
[3] Fierce Pharma